Tweet
Updated 11:58 PM ET, Sat April 3, 2021
By Kaitlan Collins, Arlette Saenz, Jake Tapper and Maggie Fox
The federal government has moved to stop any further risk of contamination at a Baltimore contract vaccine manufacturer where 15 million potential doses of Johnson & Johnson vaccine were spoiled last month, telling rival drugmaker AstraZeneca it must move its production from the plant and find somewhere else to make its vaccine.
The Emergent BioSolutions plant in Baltimore was making coronavirus vaccines under contract to both Johnson & Johnson and AstraZeneca. Last month, a batch of Johnson & Johnson "drug product" failed quality control and was taken out of production, both J&J and Emergent have said.
The federal government has directed Johnson & Johnson to fully take over its vaccine production at the plant, an administration official told CNN Saturday.
..."Johnson & Johnson is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility...
... And AstraZeneca confirmed it would stop manufacturing it vaccine, called AZD1222, at the Emergent Baltimore plant.
By Kaitlan Collins, Arlette Saenz, Jake Tapper and Maggie Fox
The federal government has moved to stop any further risk of contamination at a Baltimore contract vaccine manufacturer where 15 million potential doses of Johnson & Johnson vaccine were spoiled last month, telling rival drugmaker AstraZeneca it must move its production from the plant and find somewhere else to make its vaccine.
The Emergent BioSolutions plant in Baltimore was making coronavirus vaccines under contract to both Johnson & Johnson and AstraZeneca. Last month, a batch of Johnson & Johnson "drug product" failed quality control and was taken out of production, both J&J and Emergent have said.
The federal government has directed Johnson & Johnson to fully take over its vaccine production at the plant, an administration official told CNN Saturday.
..."Johnson & Johnson is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility...
... And AstraZeneca confirmed it would stop manufacturing it vaccine, called AZD1222, at the Emergent Baltimore plant.
Comment